Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Mar;40(3):e3646.
doi: 10.1002/dmrr.3646. Epub 2023 May 23.

Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Affiliations
Practice Guideline

Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Dane K Wukich et al. Diabetes Metab Res Rev. 2024 Mar.

Abstract

The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. This is the first guideline on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes published by the IWGDF. We followed the GRADE Methodology to devise clinical questions in the PACO (Population, Assessment, Comparison, Outcome) and PICO (Population, Intervention, Comparison, Outcome) format, conducted a systematic review of the medical literature, and developed recommendations with the rationale. The recommendations are based on the evidence from our systematic review, expert opinion when evidence was not available, and also taking into account weighing of the benefits and harms, patient preferences, feasibility and applicability, and costs related to an intervention. We here present the 2023 Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus and also suggest key future topics of research.

Keywords: Charcot foot; Charcot neuro-osteoarthropathy; Charcot neuroarthropathy; Charcot osteoarthropathy; diabetic foot; guidelines.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Metcalf L, Musgrove M, Bentley J, et al. Prevalence of active Charcot disease in the East Midlands of England. Diabet Med. 2018;35(10):1371-1374. https://doi.org/10.1111/dme.13679
    1. O'Loughlin A, Kellegher E, McCusker C, Canavan R. Diabetic charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre. Ir J Med Sci. 2017;186(1):151-156. https://doi.org/10.1007/s11845-016-1508-5
    1. Svendsen OL, Rabe OC, Winther-Jensen M, Allin KH. How common is the rare Charcot foot in patients with diabetes? Diabetes Care. 2021;44(4):e62-e3. https://doi.org/10.2337/dc20-2590
    1. International Diabetes Foundation. IDF Diabetes Atlas 10th Edition; 2021. Accessed 9 August 2022. https://www.diabetesatlas.org
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660

Publication types

MeSH terms